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Differential expression of lncRNAs 
during the HIV replication cycle: an 
underestimated layer in the HIV-
host interplay
Wim Trypsteen1, Pejman Mohammadi2, Clarissa Van Hecke1, Pieter Mestdagh3, 
Steve Lefever3,  Yvan Saeys4,5,  Pieter De Bleser4,6,  Jo Vandesompele3, Angela Ciuffi2,  
Linos Vandekerckhove1,* &  Ward De Spiegelaere1,7,*
Studying the effects of HIV infection on the host transcriptome has typically focused on protein-coding 
genes. However, recent advances in the field of RNA sequencing revealed that long non-coding RNAs 
(lncRNAs) add an extensive additional layer to the cell’s molecular network. Here, we performed 
transcriptome profiling throughout a primary HIV infection in vitro to investigate lncRNA expression at 
the different HIV replication cycle processes (reverse transcription, integration and particle production). 
Subsequently, guilt-by-association, transcription factor and co-expression analysis were performed to 
infer biological roles for the lncRNAs identified in the HIV-host interplay. Many lncRNAs were suggested 
to play a role in mechanisms relying on proteasomal and ubiquitination pathways, apoptosis, DNA 
damage responses and cell cycle regulation. Through transcription factor binding analysis, we found 
that lncRNAs display a distinct transcriptional regulation profile as compared to protein coding mRNAs, 
suggesting that mRNAs and lncRNAs are independently modulated. In addition, we identified five 
differentially expressed lncRNA-mRNA pairs with mRNA involvement in HIV pathogenesis with possible 
cis regulatory lncRNAs that control nearby mRNA expression and function. Altogether, the present 
study demonstrates that lncRNAs add a new dimension to the HIV-host interplay and should be further 
investigated as they may represent targets for controlling HIV replication.
The interplay between the human immunodeficiency virus (HIV) and the host’s cellular defenses has been 
broadly studied to elucidate the underlying viral and antiviral molecular mechanisms. These studies typically 
focused on protein-coding genes and successfully identified several host factors involved in HIV pathogene-
sis and intracellular defense1–6. However, over the past decade it has become evident from genome-wide tiling 
arrays and RNA sequencing studies that the human genome is pervasively transcribed and that the majority of 
these transcribed genomic sequences are associated with non-coding RNAs (ncRNAs) rather than protein coding 
RNAs, underpinning their widespread presence in the cellular environment and adding a new layer of complexity 
to the cell’s molecular network7–10.
The class of ncRNAs is subdivided by length into small (< 200 nt) and long (> 200 nt) non-coding RNAs 
(lncRNAs). The lncRNAs constitute the bulk of ncRNAs with current databases describing up to ~62 000 long 
non-coding RNA genes compared to the ~20 000 known protein coding genes11,12. LncRNAs form a diverse 
group of molecules that can bind to DNA, RNA or proteins and are mainly involved in the regulation of gene 
expression, chromatin organization, nucleus-to-cytoplasm trafficking, RNA maturation and protein synthesis9. 
In addition, lncRNAs are frequently co-expressed with neighboring genes and show nuclear and/or cytoplasmic 
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localization8,13. Furthermore, lncRNAs are crucial for normal cellular function and their dysregulation has already 
been linked to human diseases such as different types of cancer, autoimmune and neurodegenerative diseases14.
The ability of lncRNAs to control transcriptional processes offers unique possibilities for pathogens like HIV 
to hijack the cellular machinery and reshape gene expression in their favor15,16. Nonetheless, most attention to 
the involvement of ncRNAs in HIV-host interactions has been focused on small ncRNAs such as microRNAs 
(reviewed in refs 15 and 17). Only a few studies have aimed their attention at lncRNAs, resulting in the fact that 
the majority of these possibly relevant molecules remain unidentified18. To date, only two host lncRNAs and 
one HIV-encoded lncRNA are functionally characterized in the context of HIV infection or replication: NEAT1, 
NRON and the viral ASP-L19–22. Here, we present a focused extension study of a unique HIV time course exper-
iment and specifically investigate lncRNA expression in the context of an HIV infection to shed light on the 
HIV-lncRNA regulatory landscape23.
Materials and Methods
HIV time course experiment. Two HIV time course experiments were conducted as previously 
described23. In short, (72 × 5 × 10^6) SupT1 cells were either mock-infected or infected with 15 μ g p24 equiv-
alent of an HIV-based vector (NL4.3Δ env::eGFP, VSV.G pseudotyped) by spinoculation at 1500 g for 30 min at 
room temperature in presence of 5 μ g/ml polybrene (Sigma). After spinoculation, cells were washed and refreshed 
with culture medium (R-10). Subsequently, every two hours post infection, a fraction (3 × 10^6) of mock infected 
and infected SupT1 cells were washed with PBS and collected together with supernatant, until the 30 hour time 
point was reached.
Assays for HIV life cycle markers. Measuring HIV reverse transcription levels. DNA was extracted with 
the DNeasy Blood and Tissue kit (Qiagen) according to the manufacturer’s instructions and DNA concentrations 
were measured with NanoDrop ND-1000 (NanoDrop). Early and late HIV reverse transcription products were 
quantified by real-time PCR as described before23. All real-time PCR reactions were performed in triplicate on the 
StepOnePlus Real-Time PCR system (Applied Biosystems) using standard cycling conditions, i.e. 2′ at 50 °C, 10′ 
at 95 °C, 40 cycles of 15″ at 95 °C and 1′ at 60 °C. Relative quantification was assessed by comparative Cq method 
and the fold changes were calculated by the Δ Δ Cq method, with the 24 hour time point as a reference. HMBS 
(PGBD) was used as an endogenous control (Supplementary Data 1).
Measuring HIV integration. For the quantification of integrated HIV DNA, first an Alu-gag PCR was carried out 
and subsequently a qPCR as described above. Alu-gag PCR: using 20 ng DNA, 0.4 mM primers (end concentra-
tion) (Supplementary Data 1), and Accuprime Pfx Supermix (Life Technologies) in a 25 μ l final volume reaction. 
PCR cycling conditions were 5′ at 95 °C, followed by 25 cycles of 3″ at 95 °C, 15″ at 55 °C, 4′ at 68 °C, and finally 
10′ at 68 °C. One tenth of this first PCR was used for qPCR as described above.
Measuring HIV transcription and particle release. Viral particle release was measured in the collected superna-
tant by p24 ELISA (Abbott Murex). Viral transcription/infection rates were assessed by GFP expression measure-
ment by FACS analysis (FACS Calibur, Becton Dickinson).
Modelling HIV markers. All markers were rescaled to the 24 hour time point and calculated as previously 
described23. Graphical output was generated using the R package ggplot2 (v1.0.0) and the RStudio statistical soft-
ware environment (v0.98.1028)24.
Selection and quality control of samples for transcriptome analysis. In the two time course exper-
iments, mock-infected and infected samples were selected at each of the following four time points, capturing 
different viral processes: early infection (2 h), peak of reverse transcription (6 h), peak of integration (18 h), viral 
release (30 h). This resulted in 16 samples. Total RNA was extracted using Trizol Reagent (Invitrogen) and RNA 
quality of all samples was assessed by Experion analysis (BioRad).
Microarray analysis. The 16 selected samples were analyzed by a custom one-color microarray (8× 60 k 
microarray, Agilent-050524 Human V2.0, GPL21113) that incorporates 40 k probes for lncRNA transcripts and 
20 k probes for mRNA transcripts (microarray IDs: US45103088_255052410015, US45103088_255052410016). 
Sample preparation was performed with the Quick amp WT labelling kit (Agilent) according to the manufac-
turer’s instructions. In short, 100 ng total RNA was used per sample as input for the generation of fluorescent 
complementary RNA (cRNA). This involved cDNA synthesis and amplification with simultaneous incorporation 
of cyanine 3-labeled CTP by the T7 RNA polymerase. Subsequently, the cRNA was purified with the RNeasy kit 
(Qiagen) as instructed by the manufacturer’s protocol and RNA concentrations measured by NanoDrop ND-1000 
(Thermo Scientific). Next, 600 ng of each cRNA sample was fragmented at 60 °C for 30 min and hybridized to the 
microarray slides for 17 hours in a hybridization oven rotator (Agilent) at 65 °C. At last, microarray slides were 
washed three times with gene expression washing buffers (Agilent) containing 0.005% Triton X-102 and scanned 
with the SureScan Microarray Scanner (Agilent) using one color scan settings: AgilentG3_GX_1Color.
Microarray data processing and differential expression analysis. Raw microarray data is publicly 
available at the NCBI Gene Expression Omnibus (series GSE74818, http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc= GSE74818) and can be browsed online using the R2 data analysis tool (http://r2.amc.nl, dataset: Exp T 
cell lymphocyte Infection (lnc and coding) - Trypsteen). Processing of the raw fluorescent microarray signals and 
differential expression analysis were performed with the Bioconductor R package limma (v3.20.9)25. First, back-
ground correction and quantile normalization was applied in order to make the 16 arrays comparable. Next, con-
trol probes and low expressed probes were filtered out. Probes were considered expressed when the fluorescent 
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signal was 50% brighter than the 95% quantile of the negative control probes on at least two arrays. Subsequently, 
a linear model was fitted for each gene to estimate the variability in the data and differential expression analy-
sis was performed at each of the four selected time points. Fold changes were calculated by an empirical Bayes 
method and the returned p-values were corrected for multiple hypothesis testing by the Benjamini-Hochberg 
method26. Probes with adjusted p-values < 0.05 were considered significantly differentially expressed and annota-
tions were added to identify the gene symbols that are linked to the probes. Information on the different lncRNA 
classes was exported from LNCipedia (www.lncipedia.org), these included: intergenic, sense-overlapping, anti-
sense, intronic and bidirectional lncRNA classes. In a last step, enhancer regions (eRNAs) were filtered by making 
use of the database of predicted human enhancers (DENdb, http://www.cbrc.kaust.edu.sa/dendb/index.php)27.
qPCR validation of selected lncRNAs. cDNA synthesis on total RNA samples was performed with iScript 
(Bio-Rad) according to manufacturer’s protocol. Primers were designed with the IDT Primer Quest tool, primer 
specificity checked by NCBI BLAST analysis and secondary structures were determined with the mFold tool28. 
Primer efficiencies were tested on a standard curve of peripheral blood mononuclear cells. Next, primers were 
checked for specific amplification of the amplicon by smelting curve analysis and further used when amplifi-
cation efficiency was observed between 90–110%29. All qPCR reactions were performed with the LightCycler 
480 II (Roche) and LightCycler480 master mix (Roche). Relative quantification was performed by making use 
of reference gene normalization and the Δ Δ Cq method. Primers for following reference genes and lncRNAs 
were used: ACTB, GAPDH, UBC, lnc-BHLHE41-2, lnc-GSDMC-1, lnc-TRDMT1-1, lnc-LEF1-3, lnc-COX10-4, 
lnc-C7ORF44-1, lnc-ZBTB20-1, lnc-PABPN1L-1, lnc-GLB1L2-4, lnc-GKN2-1, lnc-LTBP3-1, lnc-AMZ2-1, 
lnc-ARRDC3-1, lnc-SYF2-1 and lnc-EXT1-1 (Supplementary Data 2, lncRNA gene names according to 
LNCipedia (www.lncipedia.org)11).
Guilt-by-association analysis. Guilt-by-association analysis was performed as described previously36. In 
short, normalized gene expression values of the 16 samples were used to build a correlation matrix with the dif-
ferentially expressed lncRNA and all expressed mRNAs. For each lncRNA, mRNAs are ranked according to their 
correlation coefficient and gene set enrichment analysis (GSEA) was performed using pathways from the Biocarta 
database37. A lncRNA was considered linked to a pathway in case of a GSEA False Discovery Rate (FDR)-value 
< 0.05. Visualization and network analysis was performed with Cytoscape using the built-in network analyzer 
tool38.
Binding and expression target analysis (BETA): transcription factor analysis. Regulatory tran-
scription factors (TFs) were determined for the differentially expressed mRNAs and lncRNAs at each time point 
through ‘binding and expression target analysis’ (BETA)39,40. In short, available Chip-seq data of 237 known tran-
scription factors and the microarray gene expression data were integrated to identify putative active or repressive 
TFs and their target genes (cut-off used for enriched TF binding sites: 0.001). Next, clustering was performed by 
CLUTO software and visualization of TF networks was conducted with Cytoscape38,41.
Cis and co-expression analysis of lncRNAs and neighboring mRNAs. Chromosomal coordinates 
based on the reference genome assembly GrCh37 were extracted from the LNCipedia database for the differ-
entially expressed lncRNA transcripts11. Additionally, the Ensembl Biomart tool was used for the retrieval of 
chromosomal coordinates of all mRNA transcripts of the corresponding reference genome30. Based on the chro-
mosomal coordinates, overlapping mRNAs and the closest neighboring mRNAs within the same topological 
associated domain (TAD) and a distance of up to 500 kb from transcription start and stop sites were determined 
for each differentially expressed lncRNA using a custom R script. Six categories were used to classify neighboring 
genes as previously described: full or partially overlapping, head to head, tail to tail, nearby to head (sense and 
antisense strand), nearby to tail (sense and antisense strand) (Supplementary Data 3)13,31. TAD information was 
downloaded from the ENCODE webserver (https://www.encodeproject.org/comparative/chromatin/#Hi-C) and 
was made available by Dixon et al32. Next, HIV interactions for the neighboring mRNAs were determined by 
making use of the HIV Interaction Database33. In addition, the epigenetic context of HIV linked mRNA-lnRNA 
pairs was determined for H3K4Me1, H3K4Me3, H3K27Ac, H3K36Me3 together with cap analysis gene expres-
sion (CAGE) peaks by making use of the Integrative Genomics Viewer34. Lastly, the co-expression database 
Co-LncRNA (http://www.bio-bigdata.com/Co-LncRNA) was browsed to determine similar co-expression events 
that correspond with our dataset35.
Results
Transcriptome changes and lncRNA involvement during HIV infection. SupT1 cells were infected 
with a VSV-G pseudotyped HIV eGFP-based vector with ~70% success, as assessed by FACS analysis of GFP 
expression (Supplementary Data 4D). Different HIV replication cycle markers were measured over time post-in-
fection: early and late reverse transcription products, integrated provirus and viral production products (Fig. 1 
and Supplementary Data 4B and 4C). These assays showed peak activity respectively at 6, 18 and 30 hours post 
-infection consistent with previous reports and reflect the three main phases in the HIV life cycle: reverse tran-
scription, integration and viral particle production (late phase)23. Subsequently, these three points were selected 
for further transcriptome analysis together with the 2-hour time point (Fig. 1 and Supplementary Data 4).
In the experimental system, 18 270 genes encompassing 12 281 mRNAs and 5989 lncRNAs were considered 
expressed using a selected threshold of 150% of the fluorescent background signal (Supplementary Data 5). In total, 
1336 genes were found differentially expressed (DE) between mock and HIV-infected samples over all time points 
after correction for multiple hypothesis testing and a false discovery rate of 5%. These included 949 mRNAs and 387 
lncRNAs, making that 29% of DE genes were lncRNAs with the majority of these DE lncRNAs originating from 
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the intergenic or antisense class (Fig. 2, Table 1, Supplementary Data 6A and 6B). Differential expression gradually 
increased, with the majority of DE genes found at the 18-hour time point or at peak of HIV integration.
Fifteen out of 387 lncRNAs were selected for subsequent RT-qPCR validation based on high fold change and 
differential expression at more than one time point. RT-qPCR confirmed differential expression of 12 out of 15 
lncRNAs identified by microarray transcriptome analysis (Supplementary Data 7). In addition, further validation 
of our DE genes included a comparison with the only previously published transcriptome dataset looking into 
mRNA and lncRNA expression upon HIV infection (Supplementary Data 8)18. Overall, we find 349 mRNAs and 
25 lncRNAs that overlap between datasets when comparing similar time points (18 hpi and 30 hpi) with Peng’s 
Figure 1. Progression of HIV replication cycle processes. The plot shows changes over time for viral 
measurements, including early reverse transcription (orange), late reverse transcription (cyan), integrated 
viral DNA (green) and virion-associated p24 protein expression (violet). Calculations for Fig. 1 are available in 
Supplementary Data 4E.
Figure 2. Overview of differential expression analysis between mock and HIV-infected cells at the 
four time points considered for transcriptome profiling. (A) Volcano plots showing all genes (grey dots). 
Significantly upregulated genes (red dots) and downregulated genes (blue dots) are highlighted for each time 
point. (B) Heatmaps of differentially expressed genes for the mRNA and lncRNA fractions. (C) Number of 
differentially expressed mRNAs and lncRNAs at peak of reverse transcription (RT), integration (IN) and viral 
particle release (LATE), respectively.
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24 hpi. This corresponded with 44–45% of the mRNAs and 8–13% of the lncRNAs that overlap at the 18 h and 30 h 
time point in our dataset, respectively.
To evaluate and suggest functional roles for these 387 lncRNAs in HIV infection, three data analysis pipelines 
were used that integrate information of mRNAs and lncRNAs. First, a guilt-by-association analysis linked to gene 
set enrichment analysis (GSEA) was conducted to match lncRNAs to biological pathways. Second, a transcrip-
tion factor analysis was performed to investigate the transcriptional regulation of lncRNA and mRNAs during 
the HIV replication cycle. Third, a co-expression analysis was performed looking at neighboring mRNA genes of 
differentially expressed lncRNAs.
Identifying biological pathways associated with lncRNAs upon HIV infection. Differentially 
expressed lncRNAs can be associated to biological pathways by applying the guilt-by-association principle with 
mRNAs. Therefore, expression profiles of all differentially expressed lncRNAs and all expressed mRNAs were 
integrated to identify associated pathways. This integrative analysis showed that 33 Biocarta pathways could be 
either negatively or positively associated to 173 DE lncRNA genes (p-value < 0.001) (Fig. 3).
The majority of differentially expressed lncRNAs are associated with the proteasome pathway and some 
smaller clusters can be found for apoptosis inhibition (VIP) and cell death, T-cell receptor signaling (TCR), 
Mini Chromosome Maintenance complex (MCM), genome integrity maintenance (BRCA1 and 2) and cell cycle 
progression (ATR), ceramide and keratinocyte pathways. Furthermore, one lncRNA, lnc-RPRML-3, is associated 
with the HIV Nef pathway and a few lncRNAs could be associated to multiple pathways, such as lnc-RPRML-3 (9 
pathways), lnc-GSDMC-1 (10 pathways) and lnc-DNAJC8-1 (10 pathways).
Transcriptional regulation of lncRNA and mRNA expression during HIV infection. To shed light 
on lncRNA and mRNA transcriptional regulation, binding and expression target (BETA) analysis was performed 
for the differentially expressed mRNAs and lncRNAs at the different time points representing the three viral 
processes (Fig. 4).
For the mRNAs, transcription factor binding sites (TFBS) are found to be significantly enriched both in the 
downregulated and upregulated fraction whereas for lncRNA only enriched TFBS were found for upregulated 
lncRNAs. In addition, upregulated mRNAs are regulated by a select number of TFs whereas downregulated 
mRNAs are enriched for more TFs.
The upregulated lncRNAs are enriched for numerous TFBS (as compared to mRNAs) and some lncRNAs, i.e. 
lnc-LTBP3-1, show very large TF seed regions (> 20 TFs), hinting at multifunctional lncRNAs that are inducible 
by many TFs.
Clustering analysis was performed to identify mRNAs and lncRNAs under similar transcriptional regulation 
for the 6 h, 18 h and 30 h time point (Supplementary Data 9A, 9B and 9C). However, data showed that lncRNA 
and mRNA have distinct transcriptional regulation profiles and small overlap in regulatory TFs, suggesting sep-
arate transcriptional control during HIV infection. In addition, most of the TFs found, have been linked to a role 
in HIV infection (Supplementary Data 10).
HIV linked co-expression of mRNA and lncRNA upon HIV infection. Neighboring or close-by genes 
show different distances and orientations to each other and can be functionally linked and show correlated expres-
sion profiles, especially when situated in the same topological associated domain (TAD)31. This co-expression can 
be caused by regulation by the same (transcription) factor or by one gene regulating the expression of the other. 
In addition, lncRNAs are demonstrated to regulate protein coding gene expression at nearby (cis acting) or distant 
(trans acting) genomic loci13. Therefore, we explored the closest mRNAs of the differentially expressed lncRNAs 
and focused on HIV linked co-expression events (Supplementary Data 3).
For each differentially expressed lncRNA we determined the closest mRNAs within the same TAD and a 
genomic distance of 500 kb upstream or downstream of transcription start/stop site and found a total of 1162 
lncRNA-mRNA pairs. Out of these, we identified a significant enrichment of 138 pairs (fisher’s exact test, 
p-value = 0.001) that contain a mRNA with previously described HIV interaction and 23 pairs that contain a 
mRNA that is also differentially expressed between mock and HIV samples (Supplementary Data 11, 12 and 13).
Differential expression (gene level)
2 hpi 6 hpi 18 hpi 30 hpi Total
Total 
unique
mRNA 1 22 673 253 949 744
 Up 1 17 571 201 790
 Down 0 5 102 52 159
lncRNA 1 16 296 74 387 328
 Up 1 16 216 56 289
 Down 0 0 80 18 98
total 2 38 969 327 1336 1072
Table 1.  Overview of differential expression analysis at the gene level. Number of differentially expressed 
genes for the four time points considered. If multiple probes were present per gene, one was used for counting 
the number of differentially expressed genes (Supplementary Data 6). hpi: hours post infection.
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To assess HIV linked co-expression events, expression profiles and epigenetic contexts were analyzed 
for five pairs that had a known mRNA-HIV interaction and were differentially expressed (Fig. 5 and Table 2, 
Supplemental Material 14). This resulted in significantly correlated expression profiles for four out of five pairs 
(Pearson correlation test, p-value < 0.05). In addition, one pair, lnc-HES5-1 & TNFRSF14, showed a negative 
expression correlation and opposite strand orientation, hinting at a possible cis regulatory lncRNA that induces 
transcriptional interference of the neighboring mRNA. Furthermore, the epigenetic context for this antisense 
lncRNA shows H3K36me3 along the transcribed region of the lncRNA and a and H3K4Me1 peak at the promotor 
site. In addition, 3 out of 5 of these co-expression events were also described in previous co-expression analysis 
reports. (Supplementary Data 15).
Discussion
Mapping the lncRNAome during the HIV replication cycle. lncRNA involvement in HIV infection 
has been poorly studied so far. Here, we explored modulation of the non-coding transcriptome throughout an 
HIV infection at selected time points representing different viral processes. This was performed with a VSVG 
pseudotyped HIV virus in order to acquire sufficient levels of infected cells to enable microarray based transcrip-
tome analysis after a single round of infection and without the need of introducing antiretroviral drugs.
In total, 29% of differentially expressed genes between infected and non-infected cells were lncRNAs, show-
ing that lncRNA involvement accounts for important and overlooked transcriptome changes during HIV infec-
tion. This is consistent with data from Peng et al. who found similar percentages of DE expressed ncRNAs in 
CD4+ T cells upon HIV infection at 12 h and 24 h post infection18. Furthermore, DE mRNAs and lncRNAs 
between our dataset and Peng et al. showed an overlap of 44–45% and 8–13%, respectively. A possible reason for 
the lower percentage of overlapping lncRNAs is that lncRNAs are found, an overage, to exert a shorter half-life 
than mRNAs and could change in a more time-dependent manner linked to specific cellular processes42. Hence, 
lncRNA expression might be influenced to a larger extent than mRNAs because the datasets differ in the time 
points considered for transcriptome profiling. Nonetheless, these overlapping mRNAs and lncRNAs validate our 
experimental setup and form ideal targets to be further investigated in the context of HIV infection. For instance, 
a well-known and characterized lncRNA, MALAT1 (lnc-SCYL1-1) is found in both datasets and is already linked 
to viral infection43. In addition, in HIV infected individuals MALAT1 is shown as a potential biomarker44. In 
this context, it would be worthwhile exploring and comparing transcriptome datasets of other viral infections 
Figure 3. Overview of the guilt-by-association analysis. (A) Network representation of differentially 
expressed lncRNAs at the 6 h (purple dots), 18 h (green dots) and 30 h (blue dots) time point. lncRNAs are 
represented in the outer circle and connected pathways (red dots) at the inside of the circle. Connections 
show a negative association (red line) or a positive association (green line). The size of all circles is scaled to 
the number of connections. (B) Overview of lncRNA associations (columns) with 33 significantly enriched 
Biocarta pathways (rows). A negative association (red rectangles) and positive association (blue rectangles) are 
represented. Pathways are clustered according to the number of mutual genes.
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(i.e. CMV, HSV) to pinpoint lncRNAs involved in the broad process of antiviral defense. Our dataset is publicly 
available and can contribute to this goal.
To date, only a few hundred lncRNAs are functionally validated45,46. This limits the possibility to associate bio-
logical meaning based on existing data analysis tools that are available for mRNAs. Therefore, we integrated three 
data analysis pipelines to associate biological functions to the differentially expressed lncRNAs.
Potential roles of lncRNA in HIV replication. Virus-host interactions drive evolution with cycles of 
alternating countermeasures. In this context, HIV circumvents host’s cellular defenses rapidly and finds numer-
ous escape mechanisms47. Interestingly, the guilt-by-association analysis showed that the majority of DE lncR-
NAs upon HIV infection could be functionally linked to the proteasome pathway. Indeed, it has been shown 
that (immuno-) proteasomes are recruited for cellular defense against incoming pathogens (i.e. HIV)48–50. These 
complexes digest viral proteins and provide small peptides that can be presented by Major Histocompatibility 
Complex I (MHC-I) molecules on the cell surface in order to be recognized and killed by other immune cells. On 
the other hand, HIV has evolved a way to counteract this by Nef-mediated downregulation of the (immuno-) pro-
teasomes and MHC-I presentation51. Other examples of proteasomal countermeasures include the Vif-mediated 
ubiquitination of the HIV restriction factor APOBEC3G/F, flagging it for proteosomal degradation, as well as 
Vpu-mediated downregulation of CD4 and tetherin through proteosomal degradation52–54. In addition, the pro-
teasome has been involved in the life cycle of many other viruses48,55. Therefore, we hypothesize that the protea-
some plays an important role in HIV escape mechanisms but also in cellular defense against pathogens and that 
lncRNAs are widely involved in this interplay between virus and host.
A second group of lncRNAs was associated with apoptotic/cell death pathways. HIV relies on a fine balance 
between pro and anti-apoptotic signals to complete its life cycle. Infected cells should survive long enough to 
allow reverse transcription of HIV RNA to DNA, integration of the DNA in the host genome and production of 
new virions. On the other hand, the host cell can induce pro-apoptotic signals as a matter of defense and prevent 
the infection from spreading56. An example of such an association is provided by lnc-ARRDC3-1 (SCAL1) which 
is overexpressed in HIV infected cells and upregulated by the Nuclear factor erythroid 2-like 2 (NFE2L2, or Nrf2), 
a transcription factor regulating survival proteins in T-cells57. In addition, knockdown of SCAL1 induces cytotox-
icity through an unknown pathway58. Our observation of SCAL1 overexpression in HIV infection supports that 
this lncRNA mediates cell survival in HIV infected T-cells.
Furthermore, several lncRNAs can be linked to the process of HIV integration. Viral integration causes DNA 
damage that is sensed by BRCA molecules that try to repair and cause cell cycle arrest before undergoing new 
DNA replication cycles15. Indeed, we identified lncRNAs linked to pathways involved in DNA repair (ATR/
BRCA), cell cycle (CellCycle, G1) and DNA replication (MCM).
One lncRNA, lnc-RPRML-3, could be positively linked to a pathway involving HIV Nef-mediated apoptosis. 
Indeed, Nef upregulates the expression of FAS Ligand on the cell surface, thereby promoting killing of uninfected 
mRNA lncRNA
6h
18h
30h
Figure 4. Transcriptional regulation for the mRNA and lncRNA fractions at the selected stages of the HIV 
replication cycle. Network representation for the upregulated (green) and downregulated (red) genes together 
with the enriched transcription factors (blue). Dark to bright color represents low to high fold change.
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bystander CD4/CD8 T cells59,60. On the other hand, we found lncRNAs linked to the VIP (vasoactive intestinal 
peptide) pathway that is a host defense mechanism to inhibit FAS ligand expression61.
Here, lncRNAs show repeated involvement in the interplay between virus and host and emphasize that these 
pathways deserve further investigation to clarify their exact contribution.
Transcriptional regulation of lncRNA and mRNA during HIV infection. The transcription factor 
analysis revealed that DE lncRNAs and mRNAs show distinct and separate transcriptional regulation profiles 
upon HIV infection. This finding is remarkable, as it suggests that lncRNAs and protein coding genes are con-
trolled by different regulatory elements. Therefore, we can speculate that these transcriptional responses are 
independent from one another, provide transcriptional feedback loops or are part of integrated (viral/anti-viral) 
mechanisms guided by different TFs.
Furthermore, we were able to link mRNA and lncRNA expression to TFs with a characterized role in HIV 
infection and/or a physical interaction with an HIV protein. For instance, downregulation of mRNAs was mainly 
regulated by PRC2 complex members SUZ12, EZH2 and CTBP2. This complex was shown to be largely involved 
Figure 5. Overview of the co-expression analysis. (A) Expression profiles for the five HIV linked co-expression 
events, i.e. lncRNA (red) and mRNA (blue) pairs. (B) Number of differentially expressed pairs between mock and 
HIV-infected samples and HIV linked pairs.
nr chr LNCipedia gene ID strand HGNC strand distance
HIV interaction 
(HIVIntDb)
1 18 lnc-RNF125-1 + RNF125 + overlap env, tat
2 6 lnc-HLA-DRB1-3 − HLA-DQB1 − overlap env, nef, gag, tat, vif, vpu
3 1 lnc-TRAF5-1 + TRAF5 + 7808 env, nef
4 10 lnc-TRDMT1-1 − VIM + 19 env, gag, gag-pol, vif, vpr
5 1 lnc-HES5-1 − TNFRSF14 + overlap env, vif
Table 2.  Co-expression analysis. Overview of five differentially expressed lncRNA-mRNA pairs with HIV 
interaction.
www.nature.com/scientificreports/
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in HIV latency establishment and epigenetic silencing62. PRC2 is also linked to proteasome and ubiquitination 
pathways which corroborates guilt-by-association findings63. Next, we found multiple TFs that were described to 
directly interact with HIV Tat. Hence, we might speculate that the lncRNA targets of these TFs are Tat induced. 
For instance, TAF1/3/7 are represented at the 18 h and 30 h time point regulating lncRNA expression. These TAFs 
take part in the TFIID-complex (transcription factor IID) that is described to be directly interacting with HIV 
Tat and can guide RNAPOLII transcribed target genes64. Beside Tat linked TFs, we found TFs that guide lncRNA 
expression with a role in the regulation of HIV transcription. The TF CHD1 is a chromatin reassembly factor 
that acts as a positive regulator of HIV transcription as upon knockdown a total block of HIV transcription was 
previously observed65. ATF3 is part of the SWI/SNF complex and is responsible for shuttling this complex to the 
HIV promoter and guide HIV transcription. This complex is well characterized in HIV infection and important 
in HIV latency66,67.
LncRNAs were, on average, connected to more TFs as compared to mRNAs, indicating that specific lncRNAs 
can be induced by multiple TFs. In addition, some lncRNAs show very large TF seed regions and can be identified 
as hubs, inducible by many TFs, one such lncRNA was MALAT1 (lnc-SCYL1-1).
Lastly, all upregulated mRNAs at the 30 h time point displayed SOX2 regulation. In our dataset a lncRNA, 
SOXOT2, was differentially expressed (upregulated) at 30 h and spans the single exon gene SOX2, indicating 
possible lncRNA regulation of mRNA transcription. Indeed, SOXOT2 has been described as a regulating factor 
of SOX2 expression in breast cancer68.
HIV linked co-expression of lncRNA and mRNA. Cis and co-expression analysis showed that expres-
sion profiles of the majority of the 23 differentially expressed lncRNA-mRNA pairs were correlated, suggesting 
that these lncRNAs are co-regulated and involved in the same biological process. Furthermore, it is possible that 
these lncRNAs regulate the expression of these mRNAs, as it has been shown for nearby lncRNAs to modulate 
mRNA expression levels13. However, functional validation of lncRNAs is needed to help understand their exact 
effects on nearby mRNAs and biological functions.
Interestingly, we identified five differentially expressed lncRNA-mRNA pairs with mRNA involvement in HIV 
pathogenesis (HIV linked co-expression). Amongst these correlated pairs we found RNF125, TRAF5 and VIM 
with a characterized role in HIV infection. RNF125 is an E3 ubiquitin ligase protein that promotes proteasomal 
degradation of RIG-I (retinoic acid-inducible gene 1), an innate immune sensor for viral RNA/DNA and activa-
tor of interferon type I, thereby reducing HIV transcription69. Therefore, we hypothesize that lnc-RNF125 may 
play a role in the RNF125-mediated downregulation of HIV replication. TRAF5 is a member of the TNF recep-
tor associated factor family (TRAFs) and involved in HIV replication in monocyte derived macrophages as an 
interaction partner of HIV Nef. This viral protein mediates the activation of TRAF2, 5 and 6, thereby inducing 
NF-ƙ B (nuclear factor kappa-light-chain-enhancer of activated B cells) release and transport to the nucleus with 
increased HIV-1 replication70. VIM (vimentin) is a major component of the cytoskeleton and can be cleaved by 
HIV-1 protease to alter the cytoskeleton for improved HIV-1 transport71. In addition, VIM is found incorporated 
in ribonuclear protein complexes that protect and keep HIV-1 transcripts in the cytoplasm, ready for viral particle 
formation72.
Although lcnRNAs have been implicated in mRNA regulation, testing specific lncRNA knockdown prior to 
HIV infection should help understand their effects on nearby mRNAs and biological functions.
Conclusion
The present study provides a comprehensive map of differentially expressed lncRNAs throughout the HIV rep-
lication cycle and reveals a new and underestimated dimension in the HIV-host interplay. Furthermore, we 
introduced integrative analysis approaches to suggest biological roles for the DE lncRNAs in the context of HIV 
infection. Although our results are based on an in vitro cell line model for HIV infection with a pseudotyped HIV 
virus, these findings suggest that lncRNAs represent promising and potential targets for controlling HIV repli-
cation. These results need to be further explored and validated in primary cell models in order to fully grasp the 
impact of specific lncRNAs on HIV replication.
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